Search the Newsreel

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Palvella Therapeutics (PVLA), Neogen (NEOG) and ACADIA Pharmaceuticals (ACAD)

This article summarizes recent analyst ratings for three healthcare stocks: Palvella Therapeutics (PVLA), Neogen (NEOG), and ACADIA Pharmaceuticals (ACAD). Palvella Therapeutics received a "Strong Buy" consensus with a significant upside potential, primarily due to a reiterated Buy rating from TD Cowen. Neogen holds a …

H.C. Wainwright reiterates Palvella Therapeutics stock rating at buy By Investing.com

H.C. Wainwright has reiterated its Buy rating on Palvella Therapeutics (NASDAQ:PVLA) with a $270.00 price target, despite a recent 21% stock decline following an updated corporate presentation. The FDA recently declined Breakthrough Therapy Designation for cVM, but the firm believes this denial has limited …

Palvella Therapeutics (PVLA) Receives a Rating Update from a Top Analyst

TD Cowen Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Raises Target Price to $267

TD Cowen has reiterated its Buy rating on Palvella Therapeutics (PVLA.US) shares. The firm also increased its price target for PVLA.US to $267, indicating continued confidence in the company's prospects.

Analysts Offer Insights on Healthcare Companies: Palvella Therapeutics (PVLA) and Armata Pharmaceuticals (ARMP)

This article highlights bullish analyst ratings for two healthcare companies: Palvella Therapeutics (PVLA) and Armata Pharmaceuticals (ARMP). TD Cowen maintained a Buy rating on Palvella with a $157.24 price target, while H.C. Wainwright reiterated a Buy rating on Armata with a $15.00 price target. …

Palvella Therapeutics (NASDAQ:PVLA) Shares Down 12.4% - Should You Sell?

[Form 4] PALVELLA THERAPEUTICS, INC. Insider Trading Activity

Palvella Therapeutics, Inc.'s Chief Operating Officer, Kathleen Goin, reported exercising and selling 4,302 shares of common stock on July 15, 2026, through a pre-arranged Rule 10b5-1 trading plan. The sales occurred across four transactions at weighted average prices ranging from $147.1365 to $150.2529 per …

Palvella Therapeutics (NASDAQ:PVLA) Shares Up 5.7% - Here's Why

Palvella Therapeutics (PVLA) Submits Initial Module of NDA For QTORIN

Palvella Therapeutics (PVLA) has submitted the initial module of its New Drug Application (NDA) to the FDA for QTORIN 3.9% rapamycin anhydrous gel, a treatment for microcystic lymphatic malformations. The company plans to complete the NDA application in the latter half of 2026 and …

Palvella Therapeutics posts corporate presentation highlighting Phase 3 SELVA wins, NDA rolling review and $262M cash

Palvella Therapeutics recently released a corporate presentation detailing positive Phase 3 SELVA results and plans for a potential U.S. launch of QTORIN™ rapamycin for microcystic LMs in the first half of 2027. The company has a strong financial position with $262 million cash and …